Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Twice-weekly carfilzomib is approved at 27 and 56 mg/m(2) to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m 2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients in comparison with twice-weekly 27 mg/m(2) carfi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica
Hlavní autoři: Bringhen, Sara, Mina, Roberto, Petrucci, Maria Teresa, Gaidano, Gianluca, Ballanti, Stelvio, Musto, Pellegrino, Offidani, Massimo, Spada, Stefano, Benevolo, Giulia, Ponticelli, Elena, Galieni, Piero, Cavo, Michele, Di Toritto, Tommaso Caravita, Di Raimondo, Francesco, Montefusco, Vittorio, Palumbo, Antonio, Boccadoro, Mario, Larocca, Alessandra
Médium: Artigo
Jazyk:Inglês
Vydáno: Ferrata Storti Foundation 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6669142/
https://ncbi.nlm.nih.gov/pubmed/30733270
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.208272
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky